F. Hoffmann-La Roche AG / Tensha Therapeutics, Inc.
2016 · Acquisition/Merger · $535M · Complete
Announcement Sentiment
93
Strongly positive
Roche acquired Cambridge, MA-based Tensha Therapeutics for $115M upfront plus up to $420M in clinical/regulatory milestones. Founded by James Bradner of Dana-Farber, Tensha developed BET-protein inhibitor TEN-010 in Phase 1b for NMC, AML, and MDS. Adds to Roche's epigenetics portfolio.